Large upfront costs for digital twin (DT) technology and lack of simulation engineering competencies block digital transformation of SMEs in machinery and construction sectors. CP-SENS (cyber-physical sensing for machinery and structures) develops a cost-effective DT framework based on digital sensing units by HBK integrated with an easy-to-use DT software developed by Aarhus University and Aalborg University. CP-SENS accompanies two SMEs, Vestas Aircoil (VA, engine cooler manufacturer) and Vienna Consulting Engineers (VCE, condition monitoring provider), throughout DT transformation and positions HBK, leader in analog sensing technology, into the growing market of digital sensing with a disruptive solution. To eliminate upfront costs, CP-SENS DT is licensed to the non-for-profit INTO-CPS Association and serves the engineering community as a vendor-neutral DT infrastructure. HBK exploits CP-SENS DT as a sale channel by subscribing as a member to the association. To enable DT transformation at national scale, DT know-how is transferred to FORCE Technology and conveyed into a 3-Day DT Crash Course for industry. CP-SENS DT allows VA to increase prototyping capacity by a factor 2 (+12 MEUR/y, +8 jobs in DK) while VCE increases monitoring capacity from 2 to 10 WT park/year (+20 MEUR/y). CP-SENS provides HBK with two strategic entry points to the digital sensing market (+12 MEUR/y, + 10 jobs in DK). Synergy with FORCE Technology enables DT transformation for +200 Danish SMEs.

In the modern digital age, secure communication is paramount for global commerce, governance, and security. While classical cryptographic techniques have been effective, they remain vulnerable to computational advances, especially the forthcoming quantum computing era. Quantum Key Distribution (QKD) with AES encryption emerges as a formidable, quantum-resistant alternative, but current QKD systems face challenges in scalability, performance, and practicality. CyberQ seeks to develop next-generation QKD systems that address these gaps, providing scalable, affordable, and robust cryptographic solutions. In doing so, CyberQ capitalizes on a business opportunity in the quantum cryptography market, projected to exceed $1 billion by 2030, while also improving security across vital sectors like banking, healthcare, and governmental agencies. This initiative aligns with national and EU strategic priorities, such as the European Quantum Flagship program, the EuroQCI initiative and the Danish strategy for quantum technology where cybersecurity is emphasized. Scientifically, CyberQ's ambition is to advance the Continuous Variable (CV) QKD system to ensure enhanced security and adaptability in intricate quantum networks. The endeavor follows three development paths: intensifying CVQKD system security, refining multi-party protocols for broader network application, and improving system resilience and miniaturization for cost-effectiveness and broad deployment.

Several chronic diseases such as cancer are complicated by cachexia, a debilitating condition characterised by loss of body weight and muscle mass with negative impact on patients' physical, mental, and social well-being. Cancer cachexia affects 80% of cancer patients and is linked with up to 30% of cancer associated deaths. Current treatment approaches fail to address the multifactorial aspect of the condition, are ineffective, and have adverse side effects. The absence of effective therapies and EMA/FDA approved drugs shows how cancer cachexia is still a major unmet medical need. In DAPHEXIA we will address this large unmet medical need by developing the first solution with potential to address the multifaceted cachexia pathology. Our innovative solution builds on the combination of the natural occurring Ghrelin hormone and Neuropeptide Y (NPY: targeting Y5 receptor) in a single dual acting peptide. We will enable the stimulation of different pathways, in a multimodal approach, with the potential to i) increase appetite, ii) decrease energy expenditure, iii) reduce inflammation, while also iv) reducing muscle wasting. Moreover, by describing the metabolic aspects and the mechanism-of-action of our dual concept we will bring new knowledge to the field cancer cachexia for the benifit of the academic society. Finally, we will by DAPHEXIA develop our selected clinical candidate from the current preclinical stage up to the stage of clinical Phase 1.